An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.
Armin Ghobadi, MD
Advertisement
Articles by Armin Ghobadi, MD
Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.
Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.
Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.
Research from a pilot trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting found above average complete response and disease-free survival rates for patients with DLBCL.
Advertisement
Latest Updated Articles
Ghobadi on the Correlation Between CD8/CD4 Ratio and Responses to Blinatumomab in Patients With DLBCLPublished: December 20th 2020 | Updated:
Armin Ghobadi, MD, on How to Interpret Preliminary Data in Patients with DLBCLPublished: January 2nd 2021 | Updated:
Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCLPublished: January 6th 2021 | Updated:
Armin Ghobadi, MD, on Blinatumomab Consolidation Post Stem-Cell Transplant for DLBCLPublished: December 10th 2020 | Updated:
Armin Ghobadi, MD, Discusses Trials Needed to Build on Blinatumomab Pilot Study DataPublished: December 28th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
2
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
3
EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma
4
Kamdar Names Potential Treatment Options Beyond Liso-cel in R/R LBCL
5
